Gofen & Glossberg’s Dynavax Technologies DVAX Stock Holding History

Gofen & Glossberg’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,700	Closed	-$145K	–	435
2018 Q3	$145K	Buy	+11,700	New	+$158K	0.01%	447

Other funds holding DVAX

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Gofen & Glossberg's DVAX Position: Q4 2018 in Review

Gofen & Glossberg sold out of Dynavax Technologies (DVAX) in Q4 2018, closing a stake of 11,700 shares — an estimated $145K sold.

Gofen & Glossberg first reported a position in DVAX in Q3 2018 and held it in 1 quarter. The position peaked at $145K in Q3 2018. 132 funds tracked by Wall St. Rank hold DVAX as of Q4 2018.

Gofen & Glossberg reported no remaining Dynavax Technologies position as of Q4 2018 after selling out during the quarter.
Gofen & Glossberg sold 11,700 Dynavax Technologies shares in Q4 2018, an estimated $145K.
Gofen & Glossberg first reported a position in Dynavax Technologies in Q3 2018 and held it in 1 quarter.
Gofen & Glossberg's Dynavax Technologies position peaked at $145K in Q3 2018.
132 funds tracked by Wall St. Rank held Dynavax Technologies as of Q4 2018.

Based on Gofen & Glossberg's 13F filing for Q4 2018, filed 15 Jan 2019.